To the Editor. —
In reading the article by Chodak et al,1 I was surprised to find that neither the differentiation nor the Gleason score of the tumors was considered in the analysis.Many physicians have the impression from clinical experience that patients with a high Gleason score or a poorly differentiated adenocarcinoma will have a poorer response to hormone manipulation than patients with more well-differentiated tumors. Since I expect that the data are available for each patient, I wonder if such an analysis has been or could be performed by this group.
Powers WE. Prognostic Indicators in Metastatic Prostate Cancer. JAMA. 1991;265(21):2808. doi:10.1001/jama.1991.03460210054016
Customize your JAMA Network experience by selecting one or more topics from the list below.